Detail akcie Becton Dickinson online

Business Summary: Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Financial Summary: BRIEF: For the six months ended 31 March 2025, Becton Dickinson and Co revenues increased 7% to $10.44B. Net income applicable to common stockholders decreased 25% to $611M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling and administrative expense increase of 8% to $2.59B (expense), Interest expense increase of 30% to $306M (expense).